Ananya Kabi¹, Ankita Kabi², Aroop Mohanty³* and Ambika Prasad Mohanty⁴

¹MBBS Student, Siksha ‘O’ Anusandhan Medical College, Bhubaneswar, Odisha, India
²Assistant Professor, Department of Emergency Medicine, AIIMS Rishikesh, Uttarakhand, India
³Assistant Professor, Department of Microbiology, AIIMS Gorakhpur, Uttar Pradesh, India
⁴Principal, Kalinga Institute of Medical Sciences, KIIT Deemed to be University, Bhubaneswar, Odisha, India

*Corresponding Author: Aroop Mohanty, Assistant Professor, Department of Microbiology, AIIMS Gorakhpur, Uttar Pradesh, India.

Received: January 27, 2022 Published: January 31, 2022

Abstract

An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first seen in Wuhan, China in December 2019. At the beginning of the pandemic, there was no drug which could be validated to be used to fight this deadly virus, but two years down the line, the armenaterium of drugs comprises of hydroxychloroquine, antivirals alone or in combination, antibiotics like azithromycin and doxycycline and low dose corticosteroids, either oral or intravenous. On the other hand, monoclonal antibodies have also played a significant role and have proved to be very effective in some cases. Here the authors have attempted to summate the role of new monoclonal antibodies and their effectiveness keeping in mind the discovery of the new variants of COVID-19.

Keywords: COVID-19; Monoclonal antibodies;

References

1. Jiang S., et al. “Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses”. Trends in Immunology5 (2020): 355-359.
2. Mohanty A., et al. “Laboratory Diagnosis of COVID19 Infection: Current Issues and Challenges: An Indian Perspective”. Journal of Advances in Medicine and Medical Research14 (2020): 10-17.
3. O'Brien MP., et al. “Subcutaneous REGEN-COV antibody combination to prevent COVID-19”. The New England Journal of Medicine 13 (2021): 1184-1195.
4. Cohen MS., et al. “Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial”. JAMA 1 (2021): 46-55.
5. Kabi A., et al. “Medical management of COVID-19: Treatment options under consideration”. International Journal of Advances in Medicine 7 (2020): 1603-1611.
6. Gupta A., et al. “Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab”. The New England Journal of Medicine 21 (2021): 1941-1950.
7. Mohanty A., et al. “Role of Rapid Antigen Test in the Diagnosis of COVID-19 in India”. Journal of Advances in Medicine and Medical Research18 (2020): 77-80.
8. Activ-Tico Ly- CoV555 Study Group., et al. “A neutralizing monoclonal antibody for hospitalized patients with COVID-19”. The New England Journal of Medicine (2021).

Citation

Citation: Aroop Mohanty., et al. “Monoclonal Antibodies In Covid-19: A Brief Insight". Acta Scientific Pharmacology 3.2 (2022): 14-17.

Copyright

Copyright: © 2022 Aroop Mohanty., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.